Promising R&D Developments and New Radiohapten Propel Y-Mabs Therapeutics to a Buy Rating

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Y-Mabs Therapeutics (YMAB – Research Report) today and set a price target of $11.00.

Robert Burns has given his Buy rating due to a combination of factors related to Y-Mabs Therapeutics’ ongoing research and development efforts. The company’s recent R&D day highlighted promising data from their Phase 1/2 trial of GD2-SADA, which is being tested in patients with recurrent or refractory metastatic solid tumors. The trial results indicated effective tumor uptake and a dose-dependent serum uptake of GD2-SADA, which is crucial for the treatment’s efficacy.
Furthermore, Y-Mabs is transitioning to a new proprietary radiohapten, Proteus, which could enhance the therapeutic potential of their treatments. This new compound is expected to broaden the range of isotopes available for theranostic applications, potentially improving outcomes. The planned incorporation of Proteus into future clinical trials, along with the anticipated launch of a dose escalation study, supports the positive outlook for Y-Mabs’ pipeline, justifying the Buy rating.

According to TipRanks, Burns is an analyst with an average return of -17.7% and a 29.80% success rate. Burns covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Zymeworks, and BioNTech SE.

In another report released on May 29, JonesTrading also reiterated a Buy rating on the stock with a $18.00 price target.